Research Directory

Commentary: The outlook for biotech seems rosy - for now

Read more

Outlook brightens for regenerative medicine

Read more

Targeting new medicines at Roche

Read more

MorphoSys Innovation Capital: A venture fund with appetite for platforms

Read more

Banner year for biotechs

Read more

What entrepreneurs should know about China

Read more

The promise of episomal reprogramming

Read more

Fully human antibodies - myths and magic bullets

Read more

Debate heats up over access to clinical trial data

Read more

The Special Protocol Assessment: Regulatory success is not guaranteed

Read more